Related Experiment Video
Updated: May 13, 2026
06:23
The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
Proton MRS in mild cognitive impairment
1Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA. kantarci.kejal@mayo.edu
Journal of Magnetic Resonance Imaging : JMRI
|March 26, 2013
Summary
Proton magnetic resonance spectroscopy ((1)H MRS) shows promise for identifying causes of mild cognitive impairment (MCI) and tracking neuronal dysfunction. This technique may offer critical biomarkers for early Alzheimer's disease (AD) diagnosis and progression.
Area of Science:
- Neurology
- Radiology
- Biochemistry
Background:
- Mild cognitive impairment (MCI) is a precursor to dementia, often Alzheimer's disease (AD).
- Current diagnostic tools for MCI lack specificity for underlying pathologies.
- Heterogeneous pathologies, including AD and cerebrovascular disease, contribute to MCI.
Purpose of the Study:
- To evaluate quantitative magnetic resonance imaging (MRI) techniques for early MCI diagnosis and progression monitoring.
- To explore the utility of proton magnetic resonance spectroscopy ((1)H MRS) in identifying MCI etiologies.
- To investigate (1)H MRS as a biomarker for neuronal dysfunction and glial activation in MCI.
Main Methods:
- Quantitative MRI techniques assessing anatomical, biochemical, microstructural, functional, and blood-flow changes.
- Proton magnetic resonance spectroscopy ((1)H MRS) for metabolite marker analysis.
- Autopsy cohort analysis to correlate pathologies with clinical presentation.
Main Results:
- Various quantitative MRI techniques are under evaluation for MCI.
- (1)H MRS metabolite markers show potential for identifying MCI etiologies in the elderly.
- Pathological heterogeneity in MCI is confirmed in autopsy studies.
Conclusions:
- Quantitative MRI offers potential surrogate measures for MCI diagnosis and progression.
- (1)H MRS may serve as a critical biomarker for pathophysiological processes in MCI, including neuronal dysfunction and glial activation.
- Further research into (1)H MRS is crucial for understanding and managing MCI.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...